ArticleCNS neuroscience & therapeutics2025
The Role of TCD in Assessing Postoperative Collateral Development and Long-Term Clinical Outcome in Moyamoya Disease.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ultrasonographic assessment of bypass capacity after revascularization surgery in moyamoya disease: a systematic review and single-arm meta-analysis.Acta neurochirurgica · 2025Pooled it
- Molecular and multimodal biomarkers in Moyamoya disease: from pathogenic mechanisms to clinical translation.European journal of medical research · 2026Review
- Advances in cerebrovascular reserve function assessment for moyamoya disease.BMJ neurology open · 2026Review
- Emerging innovations in the management of pediatric moyamoya disease.World journal of pediatrics : WJP · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimsTo explore the role of transcranial Doppler (TCD) parameters after encephaloduroarteriosynangiosis (EDAS) to identify collateral development in moyamoya disease (MMD) and assess the relationship between these collateral formations and long-term postoperative cerebrovascular events.
methodsA retrospective analysis of 91 MMD patients who underwent EDAS. Patients were categorized into rich or poor collateral groups based on postoperative angiography. TCD was used to monitor changes in hemodynamic parameters pre-and post-surgery. The association between clinical outcome, TCD parameters, and the degree of collateral development was investigated. OUTCOMES: Ninety-one patients were assessed, with 45 (49.0%) exhibiting rich collaterals and 46 (51.0%) showing poor collaterals. Over 2 years, the rich collateral group experienced significantly fewer cerebrovascular events than the poor collateral group (p = 0.041). Postoperative evaluations demonstrated significant improvements in hemodynamic parameters within the rich collateral group, including increases in peak-systolic velocity (PSV), end-diastolic velocity (EDV), and mean velocity (MV), alongside decreases in resistance index (RI) and pulsatility index (PI) (p < 0.05). An EDV cutoff of > 16.62 cm/s in the superficial temporal artery (STA) effectively identified collateral development, yielding an area under the curve (AUC) of 0.907. Additionally, multivariate analysis revealed a strong association between preoperative MV of the STA and collateral formation.
conclusionTCD sonography is a non-invasive modality essential for assessing cerebral hemodynamics after revascularization in MMD. Collateral development shown on angiography corresponds to hemodynamic changes reflected in TCD. The postoperative EDV of the STA was a vital indicator of effective collaterals. Patients with well-developed collaterals were at a lower risk of long-term cerebrovascular events post-surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.